This surgical growth story is taking shape! ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏
 ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏




 

[Morning Watchlist]
[[link removed]]

Friday, September 11, 2026  •  Your Daily Market Briefing

You are receiving this email because you are subscribed to MORNING
WATCHLIST FROM BEHIND THE MARKETS.
If you no longer wish to receive these emails, please unsubscribe here
[[link removed]].

Sponsored Content

This ad is sent on behalf of This has been disseminated by BioStem
Technologies, Inc. 

BSEM IS GOING BIGGER: THE SURGICAL GROWTH STORY IS TAKING SHAPE! 

[BSEM] [[link removed]]

BIOSTEM IS EXPANDING BEYOND TRADITIONAL WOUND CARE WITH A $26B
SURGICAL OPPORTUNITY, GROWING HOSPITAL REVENUE AND A MAJOR
MANUFACTURING SHIFT ON THE HORIZON!

Greetings,

BIOSTEM TECHNOLOGIES (NASDAQ: BSEM) is entering a potentially
important phase of its growth story and this time, the biggest
opportunity may not be the Nasdaq listing itself…..

The company is making a major push deeper into HOSPITALS AND SURGICAL
PROCEDURES, following its BIOTISSUE ASSET ACQUISITION, while
simultaneously working to bring key manufacturing operations
in-house. 

With hospital revenue climbing, an expanding sales force, access to
major hospital purchasing organizations and a growing body of clinical
evidence, BSEM is positioning itself for a much larger role in the
regenerative medicine market.

AND THERE’S ANOTHER PIECE YOU MAY WANT TO KEEP ON THE RADAR:
MANUFACTURING. 

BSEM plans to transition production of its acquired Neox® and
Clarix® product lines into its Florida facility, potentially creating
a path toward recovering some of the margin compression caused by the
current manufacturing arrangement.

THIS COMBINATION: SURGICAL EXPANSION + HOSPITAL PENETRATION +
MANUFACTURING CONTROL + CLINICAL CATALYSTS — COULD BE WHERE THE
BIGGER OPPORTUNITY STARTS TO EMERGE!

THE BIG SHIFT: GOING AFTER SURGERY

BSEM’S BioTissue acquisition is changing the company’s revenue mix
and expanding its reach far beyond traditional physician-office wound
care.

According to the company, approximately 87% OF CURRENT REVENUE IS NOW
TIED TO SURGICAL PROCEDURAL REIMBURSEMENT, compared with just 13% from
product-based reimbursement. 

That shift gives BSEM greater exposure to hospital-based procedures
and commercial payers while reducing its reliance on the CMS
reimbursement environment that has pressured portions of the broader
wound-care market.

The numbers are already showing the impact. 

HOSPITAL REVENUE REACHED $6.7 MILLION IN THE SECOND QUARTER, UP FROM
$5.7 MILLION IN THE FIRST QUARTER, WHILE THE ACQUIRED NEOX® AND
CLARIX® PORTFOLIOS WERE THE PRIMARY CONTRIBUTORS TO QUARTERLY
REVENUE.

That’s a meaningful evolution for a company that historically had a
much heavier focus on chronic wound care.

A $26B MARKET IS NOW IN SIGHT

BSEM estimates its total addressable U.S. market at approximately $26
BILLION, including roughly $11 BILLION ACROSS SURGICAL SPECIALTIES
such as orthopedics, foot and ankle, spine, urology and colorectal
procedures.

That gives the company _multiple potential avenues for expansion
_rather than relying on a single product or indication.

The company is already targeting areas such as UROLOGY, FOOT AND ANKLE
AND ORTHOPEDIC PROCEDURES, while its products are supported by a
growing body of clinical literature. 

BSEM says its technologies and products have been associated with more
than 400 publications and 1.2 million product applications.

For a regenerative medicine company looking to expand inside hospital
systems, that clinical evidence could become increasingly important as
physicians and hospital committees demand stronger data before
adopting new technologies.

HOSPITAL ACCESS COULD BE A MAJOR GROWTH ENGINE

BSEM isn’t trying to build its hospital business from scratch!

The company currently has FOUR GPO CONTRACTS COVERING APPROXIMATELY
TWO-THIRDS OF U.S. HOSPITAL BEDS, giving its products purchasing
eligibility across a significant portion of the U.S. hospital market.

Of course, GPO access does not guarantee sales. Hospitals still
require physician demand and approval from value analysis committees.
But the infrastructure is already there and BSEM is working to expand
the commercial engine behind it.

The company currently has 30 DIRECT SALES REPRESENTATIVES, with plans
to increase its direct sales force to approximately 40 REPRESENTATIVES
BY YEAR-END.

The strategy is straightforward: get more salespeople in front of more
physicians, target hospitals with significant procedural volumes and
use clinical evidence to drive adoption.

MANUFACTURING SHIFT COULD CHANGE THE MARGIN STORY

This may be one of the most interesting pieces of the BSEM story.

BioStem currently purchases Neox® and Clarix® products from
BioTissue under a cost-plus manufacturing arrangement. That
contributed to a significant decline in gross margin, which fell to
61% IN THE SECOND QUARTER FROM 94% IN THE SECOND QUARTER OF 2025.

But management is working toward a major change.

BioStem plans to bring Neox® and Clarix® manufacturing in-house at
its Pompano Beach, Florida facility during the first half of 2027,
with particulate products expected to follow later.

The facility includes approximately 6,100 SQUARE FEET OF DEDICATED
SPACE AND 3,000 SQUARE FEET OF ISO CLEAN-ROOM SPACE, with management
estimating capacity of roughly 100,000 SQUARE CENTIMETERS PER MONTH.

If the transition goes according to plan, vertical integration could
give BSEM greater control over production and potentially provide a
path toward margin recovery as the acquired business scales.

In other words, the manufacturing investment being made today could
become an important piece of the profitability story tomorrow.

CLINICAL DATA COULD HELP OPEN MORE DOORS

The commercial expansion is being paired with an aggressive push to
build the clinical evidence behind BIOSTEM’S products.

Management has highlighted data involving Clarix® 1K in
robot-assisted radical prostatectomy procedures, as well as clinical
evidence in foot and ankle procedures showing shorter healing times
among certain patient groups.

BioStem also plans to publish additional clinical data involving
diabetic foot ulcers and venous leg ulcers during 2026, while
continuing to develop real-world evidence across its surgical
applications.

The company’s proprietary BioREtain® technology remains another
important part of the platform, designed to preserve the structural
integrity and biological components of placental-derived tissue used
in regenerative medicine products.

For BSEM, more clinical evidence could mean more opportunities to
engage surgeons, hospital committees and payers with data supporting
the use of its products.

FDA CLEARANCE ADDS ANOTHER CATALYST

BSEM is also working to turn regulatory progress into commercial
opportunities.

The company announced that BioTissue received FDA 510(K) CLEARANCE FOR
CLARIX FLO AND NEOX FLO IN JUNE, a milestone management believes could
support additional marketing claims and more evidence-based
conversations with surgeons and hospital committees.

BSEM is targeting a CATALYZE PRODUCT LAUNCH BY THE END OF 2026,
creating another potential catalyst for investors to watch as the
company expands its product portfolio.

With additional clinical publications, product launches and regulatory
developments ahead, BSEM has several potential catalysts developing at
the same time.

REVENUE IS GROWING

BioStem reported $7.9 MILLION IN SECOND-QUARTER REVENUE, up 29% from
$6.1 million in the first quarter, while management guided for fiscal
2026 revenue of $26 MILLION TO $29 MILLION.

NASDAQ… JUST THE BEGINNING?

BSEM officially uplisted to the Nasdaq Capital Market on August 7,
giving the company access to a broader investment audience and greater
visibility among investors.

BUT THE MORE IMPORTANT QUESTION NOW IS WHAT BSEM DOES WITH THAT
VISIBILITY.

The company has gone from a smaller wound-care operation toward a
broader regenerative medicine platform with hospital exposure,
surgical applications, GPO relationships, an expanded sales force,
clinical catalysts and a vertically integrated manufacturing strategy.

THE NASDAQ LISTING MAY HAVE OPENED THE DOOR.

WALL STREET COVERAGE ADDS ANOTHER LAYER OF INTEREST

The company is also attracting attention from research firms.

ZACKS SMALL-CAP RESEARCH HAS MAINTAINED A $25.50 PRICE TARGET, while
H.C. WAINWRIGHT HAS INITIATED COVERAGE WITH A BUY RATING AND A $7
PRICE TARGET, according to the information provided.

Those targets aren't guarantees, of course, but they highlight the
significant valuation gap that some analysts see between BSEM'S
current market value and what the company could potentially be worth
if its clinical, commercial and reimbursement strategy plays out.

THE BOTTOM LINE

BSEM COULD BE ONE OF BIOTECH’S HIDDEN GEMS.

With a rapidly expanding hospital footprint, a growing surgical
pipeline, multiple clinical catalysts and a manufacturing strategy
designed to unlock stronger margins, BSEM is quietly building
something much bigger.

The next phase for BSEM could come down to a handful of key
milestones: HOSPITAL REVENUE GROWTH, SALES-FORCE EXPANSION, ADOPTION
OF NEOX® AND CLARIX®, ADDITIONAL CLINICAL PUBLICATIONS, THE CATALYZE
LAUNCH, REGULATORY DEVELOPMENTS AND THE PLANNED 2027 MANUFACTURING
TRANSITION.

If BSEM can continue expanding its surgical footprint while improving
manufacturing economics, the company could be positioning itself for a
very different financial profile than the one it has today. 

THE PIECES ARE COMING TOGETHER SO KEEP BSEM ON YOUR RADAR!
[[link removed]]

We are issuing this disclosure in compliance with Section 17(b) of the
Securities Act, which requires us to disclose any compensation
received or expected to be received in cash or in kind in connection
with the purchase or sale of any security.

This is a paid advertisement for BioStem Technologies, Inc. (BSEM).
 Behind the Markets will receive compensation from Sideways Frequency
in connection with multiple mailings for this advertisement. Behind
the Markets is paid a fixed cash fee for multiple mailings for this
advertisement in the amount of $7,500. This communication is for
informational and advertising purposes only and does not constitute
investment advice, an offer, or a recommendation to buy or sell any
security. Investors should conduct their own independent research and
consult a qualified financial professional before investing. 

This disclosure is made as of 09/11/2026.

You are receiving this email because you are subscribed to Morning
Watchlist from Behind the Markets. If you no longer wish to receive
these emails, please unsubscribe here
[[link removed]].

For more information about our privacy practices, please review our
Privacy Policy
[[link removed]]
or our Legal Notices
[[link removed]].

Our mailing address is:
Behind the Markets, LLC
4260 NW 1st Avenue, Suite 55
Boca Raton, FL 33431

Visit our website here: Behind the Markets
[[link removed]]

Copyright © 2026 Behind the Markets, LLC, All rights reserved.